Multiple Myeloma

Clinical Trials

Below is a list of Multiple Myeloma clinical trials from the clinical trials database at Mayo Clinic.

This list includes only trials about which Mayo researchers choose to publish information. Mayo Clinic may be conducting other trials which are not in this database. Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.

A Phase 2, Study of Carfilzomib in Patients with Relapsed Multiple Myeloma
Patients are being asked to take part in this research study because they have a cancer of the blood called multiple myeloma.
The purpose of this study is to see how safe and effective an investigational new drug [a drug that has not received approval by the U.S. Food and Drug Administration (FDA)] called carfilzomib is in patients with multiple myeloma who have received prior treatment for their disease. The research staff want to find out what effects, good and/or bad, it has on the patient and their cancer.
Carfilzomib is a type of drug called a proteasome inhibitor. A proteasome is a protein found within cells that has the important role of identifying and marking damaged proteins that are needed to be destroyed by the cell for survival. The inhibition of the proteasome allows for damaged protein to build up within cells. This build up of damaged protein causes the cell to die. In the laboratory, the way carfilzomib works is similar to another drug that has been approved by the FDA to treat Multiple Myeloma.
Read more

A Phase I/II Study of the Raf Kinase/VEGFR Inhibitor Sorafenib (Bay 43-9006) in Combination with the mTOR Inhibitor RAD001 (Everolimus, Certican) in Patients with Relapsed Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma
Sorafenib and RAD001 are two drugs that block some of the main switch pathways in tumor cells from working properly. When combined, it is hoped that they might prevent the cells from growing or cause them to die. Preliminary experiments with RAD001 in lymphoma patients have shown definite anti-tumor activity.
Read more

A Phase II Trial of CC-4047 (Actimid) Plus Dexamethasone (Decadron) in Patients with Relapsed or Refractory (Resistant) Multiple Myeloma
Patients are being asked to take part in this research study because they have multiple myeloma that has recurred after initial treatment. CC-4047 is a new drug that is related to thalidomide and lenalidomide. The research staff is studying the effects, both good and bad, of CC-4047 in combination with dexamethasone in patients with multiple myeloma that has recurred after initial treatment.
Read more

ACF4375g: An Open-Label, Phase 1b, Dose-Escalation Study of the Safety and Pharmacology of the Anti-CD40 Monoclonal Antibody SGN-40 Administered in Combination with Bortezomib (Velcade, PS-341) in Patients with Relapsed or Refractory (resistant) Multiple Myeloma
Patients are being asked to take part in this research study because they have a type of cancer called multiple myeloma that has reoccurred after initially responding to treatment or they have failed to respond to a previous treatment. The purpose of this study is to test the safety of SGN-40 at different dose levels when combined with a drug called bortezomib (Velcade). The research staff want to find out what effects, good and/or bad, it has on patients and their multiple myeloma. It will also determine the highest tolerated dose of SGN-40 that may be used in other studies.




The use of SGN-40 in this research study is experimental which means that it is not approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma. Bortezomib is approved by the FDA for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Read more

Comparison of Peripheral Blood Stem Cell Transplantation with Bone Marrow Transplantation for the Treatment of Serious Hematological Malignancies
This research study will compare the outcomes of study participants who have had peripheral blood stem cell transplantation from unrelated donors with those who have had bone marrow transplant from unrelated donors for the treatment of serious hematological malignancies.

Two types of stem cell transplantation have been used to treat patients with certain types of serious diseases. Stem cells can be obtained from bone marrow or from circulating blood (peripheral blood stem cells). Participants may be treated with a transplant of either bone marrow or peripheral blood stem cells (PBSC) from unrelated donors.

Both of these types of transplant have been successful for the treatment of leukemia and myelodysplasia. The goal of this research study is to see if there are better results using a bone marrow transplant or a PBSC transplant from unrelated donors.
Read more

Systemic Administration of (Edmonston Strain) of Measles Virus, Genetically Engineered to Express NIS, with or without Cyclophosphamide in Patients with Recurrent or Refractory Multiple Myeloma (MC038C)
Researchers are trying to find new treatments that may be more effective at treating multiple myeloma. The "drug" used in this trial is a modified version of the measles virus used to vaccinate children. The virus has been altered by having an extra gene (piece of DNA) added for a protein called NIS inserted into it. NIS is normally found in the thyroid gland (a small gland in the neck) and helps the body concentrate iodine. Having this additional gene will make it possible to track where the virus goes in a patient's body.

Both the unmodified measles vaccination virus (MV-Edm) and this modified virus (MV-NIS) have been shown to multiply in and destroy myeloma cells in the test tube and in research mice. Researchers hope the MV-NIS will have the same effect in myeloma cells in patients. Because most people have either had the measles or had a measles vaccination, the patient's body may rapidly destroy the MV-NIS. This will be monitored by blood, urine, mouth rinsing, and imaging tests. It is for this reason, however, that some patients may receive in addition to the MV-NIS, a drug called cyclophosphamide. Cyclophosphamide is a common chemotherapy drug which also suppresses the immune system. If researchers find that patients rapidly destroy the MV-NIS, future patients will receive a low dose of cyclophosphamide before the MV-NIS injection to reduce the ability of the patient's immune system to quickly destroy the MV-NIS. Patients will be informed if they will be receiving MV-NIS alone or MV-NIS and the cyclophosphamide.

This virus has not been tested in humans before and it is not a vaccine.

This study is being done to:

-Test the safety of the administration through a vein (IV) of MV-NIS (with or without cyclophosphamide)
-Determine the maximum dose of the virus that can be safely administered in patients with myeloma (with and without cyclophosphamide)
-Determine the fate (where it is, how long it stays there, how it multiplies) of the virus in the body using I-123 with gamma camera imaging. These small doses of radioactive isotope (iodine-123) are used routinely to image the thyroid and other organs without any known problems
-Evaluate the effects of the virus on the body using blood, throat swabs, urine samples and bone marrow biopsies
-Evaluate whether this investigational virus can have any impact on the amount of disease present in patients
Read more

Zevalin Radionimmunotherapy with High-Dose Melphalan and Stem Cell Transplant for Multiple Myeloma (MC048A)
This research study is being done to:

• Test the safety of an antibody (a protein generated by immune system) called rituximab and a radioactive antibody called Yttrium-90 Zevalin when they are given together with standard high-dose melphalan chemotherapy and stem cell transplant
• See what effects (good and bad) this combination therapy has on you and your multiple myeloma
• Learn what effect this treatment has on your blood B lymphocytes after transplant
• See what effects the radioactive antibody (Yttrium-90 Zevalin) has on your myeloma cells.